Pfizer Darifenacin, Yamanouchi NDAs Filed For Urinary Incontinence

The urinary incontinence market could see the next wave of anticholinergic agents in 2003, with recent NDA submissions for two highly selective muscarinic receptor antagonists: Pfizer's darifenacin and Yamanouchi's solifenacin (YM-905)